Jiangsu Aland Nutrition Co., Ltd.
PrivateLast Round
Debt
Sep 8, 2026
Est. Valuation
$1.38B
Total Funding Raised
$231.3M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Jiangsu Aland Nutrition Co., Ltd. operates in Healthcare & Life Sciences and is based in Taizhou. Its latest recorded funding round was a Debt round in September 2026.
Jiangsu Aland Nutrition Co., Ltd. is a nutraceutical and dietary supplement company that specializes in the research, development, and production of vitamins, minerals, herbal extracts, and functional foods.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Pharma Supply Chain, Smart Manufacturing, Supply Chain
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Jiangsu Aland Nutrition Co., Ltd. Comparables
Compare Jiangsu Aland Nutrition Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Shandong Luwei Pharmaceutical Co., Ltd. | 87% | |
| Anhui Fengyuan Group Co., Ltd. | 77% | |
| Stern-Wywiol Gruppe | 76% |
For institutional investors. Book with your work email.
Jiangsu Aland Nutrition Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Sep 8, 2026 | ||||
| M&A | Aug 1, 2025 | ||||
| Series A Extension | Dec 23, 2020 | ||||
| Private Equity | Jun 1, 2017 |
For institutional investors. Book with your work email.
Jiangsu Aland Nutrition Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Affinity Equity Partners | Series A Extension |
| Goldman Sachs Growth Equity | Private Equity |
| The Export-Import Bank of China | Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 8, 2026
$34M raised from The Export-Import Bank of China.
- Aug 1, 2025
Closed a $1.5B M&A round.
For institutional investors. Book with your work email.
Jiangsu Aland Nutrition Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Jiangsu Aland Nutrition Co., Ltd.'s valuation, stock price, and market status.
Is Jiangsu Aland Nutrition Co., Ltd. a public or private company?
Jiangsu Aland Nutrition Co., Ltd. is a private company.
What is the current stock price of Jiangsu Aland Nutrition Co., Ltd.?
Jiangsu Aland Nutrition Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Jiangsu Aland Nutrition Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Jiangsu Aland Nutrition Co., Ltd. worth (valuation)?
Jiangsu Aland Nutrition Co., Ltd.'s valuation is estimated at $1.4B based on funding round data.
Can I buy Jiangsu Aland Nutrition Co., Ltd. stock?
Jiangsu Aland Nutrition Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Jiangsu Aland Nutrition Co., Ltd.'s last funding round?
Jiangsu Aland Nutrition Co., Ltd.'s most recent funding round was Debt on September 8, 2026.
Who are the main investors in Jiangsu Aland Nutrition Co., Ltd.?
Key investors in Jiangsu Aland Nutrition Co., Ltd. include Affinity Equity Partners, Goldman Sachs Growth Equity, The Export-Import Bank of China.
Will Jiangsu Aland Nutrition Co., Ltd. IPO soon?
No public IPO plans have been announced for Jiangsu Aland Nutrition Co., Ltd..
How can I track Jiangsu Aland Nutrition Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Jiangsu Aland Nutrition Co., Ltd.'s shares on secondary markets.